Wu Jogin R, Zhou Chaoming, Majumder Rinku, Powers Daniel D, Weinreb Gabriel, Lentz Barry R
Department of Biochemistry and Biophysics, CB 7260, University of North Carolina at Chapel Hill, 27599-7260, USA.
Biochemistry. 2002 Jan 22;41(3):935-49. doi: 10.1021/bi0116893.
Activation of prothrombin by factor X(a) requires proteolysis of two bonds and is commonly assumed to occur via by two parallel, sequential pathways. Hydrolysis of Arg(322)-Ile(323) produces meizothrombin (MzII(a)) as an intermediate, while hydrolysis of Arg(273)-Thr(274) produces prethrombin 2-fragment 1.2 (Pre2-F1.2). Activation by human factor X(a) of human prothrombin was examined in the absence of factor V(a) and in the absence and presence of bovine phosphatidylserine (PS)/palmitoyloleoylphosphatidylcholine (25:75) membranes. Four sets of data were collected: fluorescence of an active site probe (DAPA) was sensitive to thrombin, MzII(a), and Pre2-F1.2; a synthetic substrate (S-2238) detected thrombin or MzII(a) active site formation; and SDS-PAGE detected both intermediates and thrombin. The fluorescence data provided an internal check on the active site and SDS-PAGE measurements. Kinetic constants for conversion of intermediates to thrombin were measured directly in the absence of membranes. Both MzII(a) and Pre2-F1.2 were consumed rapidly in the presence of membranes, so kinetic constants for these reactions had to be estimated as adjustable parameters by fitting three data sets (thrombin and MzII(a) active site formation and Pre2 appearance) simultaneously to the parallel-sequential model. In the absence of membranes, this model successfully described the data and yielded a rate constant, 44 M(-1) s(-1), for the rate of MzII(a) formation. By contrast, the parallel-sequential model could not describe prothrombin activation in the presence of optimal concentrations of PS-containing membranes without assuming that a pathway existed for converting prothrombin directly to thrombin without release from the membrane-enzyme complex. The data suggest that PS membranes (1) regulate factor X(a), (2) alter the substrate specificity of factor X(a) to favor the meizothrombin intermediate, and (3) "channel" intermediate (MzII(a) or Pre2-F1.2) back to the active site of factor X(a) for rapid conversion to thrombin.
凝血酶原被因子X(a)激活需要水解两个肽键,通常认为是通过两条平行的连续途径发生的。水解精氨酸(322)-异亮氨酸(323)产生中间产物中凝血酶(MzII(a)),而水解精氨酸(273)-苏氨酸(274)产生凝血酶原2片段1.2(Pre2-F1.2)。在不存在因子V(a)以及不存在和存在牛磷脂酰丝氨酸(PS)/棕榈酰油酰磷脂酰胆碱(25:75)膜的情况下,检测人因子X(a)对人凝血酶原的激活作用。收集了四组数据:活性位点探针(DAPA)的荧光对凝血酶、MzII(a)和Pre2-F1.2敏感;合成底物(S-2238)检测凝血酶或MzII(a)活性位点的形成;SDS-PAGE检测中间产物和凝血酶。荧光数据为活性位点和SDS-PAGE测量提供了内部对照。在不存在膜的情况下直接测量了中间产物转化为凝血酶的动力学常数。在存在膜的情况下,MzII(a)和Pre2-F1.2都迅速消耗,因此这些反应的动力学常数必须通过将三组数据(凝血酶和MzII(a)活性位点的形成以及Pre2的出现)同时拟合到平行-连续模型中作为可调参数来估计。在不存在膜的情况下,该模型成功地描述了数据,并得出MzII(a)形成速率的速率常数为44 M(-1) s(-1)。相比之下,平行-连续模型无法描述在含有最佳浓度PS的膜存在的情况下凝血酶原的激活,除非假设存在一条将凝血酶原直接转化为凝血酶而不从膜-酶复合物中释放的途径。数据表明,PS膜(1)调节因子X(a),(2)改变因子X(a)的底物特异性以有利于中凝血酶中间产物,以及(3)将中间产物(MzII(a)或Pre2-F1.2)“引导”回到因子X(a)的活性位点以快速转化为凝血酶。